Calcium phosphate-based nanomedicine mediated CRISPR/Cas9 delivery for prostate cancer therapy

Introduction: Erythropoietin producing hepatocyte receptor A2 (EphA2) is widely presented in the tumor cells, closely related to tumor cell migration, not cell apoptosis and proliferation. Based on its high expression in castration-resistant prostate cancer (CRPC), we herein develop a CRISPR-Cas9-ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Chao-Gang, Zhang, Rui, Wei, Lan-Yi, Pan, Peng, Zu, He, Liu, Ya-Zhen, Wang, Yong, Shen, Jun-Kang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Bioengineering and Biotechnology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794984/
https://www.ncbi.nlm.nih.gov/pubmed/36588949
http://dx.doi.org/10.3389/fbioe.2022.1078342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794984/
https://www.ncbi.nlm.nih.gov/pubmed/36588949
http://dx.doi.org/10.3389/fbioe.2022.1078342

Ejemplares similares